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Abstract
Background: Monomers of the collectin surfactant associated protein-A (SP-A) are arranged in trimers and higher
oligomers. The state of oligomerization differs between individuals and likely affects SP-A’s functional properties.
SP-A can form aggregates together with other SP-A molecules. Here we report and assess a test system for the
aggregate forming properties of SP-A in serum and broncho-alveolar lavage samples.
Methods: Anti-SP-A antibodies fixed to latex beads bound SP-A at its N-terminal end and allowed the interaction
with other SP-A molecules in a given sample by their C-terminal carbohydrate recognition domain (CRD) to
agglutinate the beads to aggregates, which were quantified by light microscopy.
Results: SP-A aggregation was dependent on its concentration, the presence of calcium, and was dose-
dependently inhibited by mannose. Unaffected by the presence of SP-D no aggregation was observed in absence
of SP-A. The more complex the oligomeric structure of SP-A present in a particular sample, the better was its
capability to induce aggregation at a given total concentration of SP-A. SP-A in serum agglutinated independently
of the pulmonary disease; in contrast SP-A in lung lavage fluid was clearly inferior in patients with chronic
bronchitis and particularly with cystic fibrosis compared to controls.
Conclusions: The functional status of SP-A with respect to its aggregating properties in serum and lavage samples
can be easily assessed. SP-A in lung lavage fluid in patients with severe neutrophilic bronchitis was inferior.
Background
Pulmonary surfactant covers the alveoli and terminal
airspaces as a complex film made of lipids (90% by
mass) and proteins. In the lungs, SP-A is the most
abundant surfactant protein by weight. SP-A belongs
like SP-D to a family of innate host defence proteins
termed collectins because of the presence of a collage-
nous and a lectin-like domain [1].
The SP-A monomer consists of 228 amino acids and
has a molecular weight of 26-32 kDa. Four domains can
be differentiated in the primary structure [2]. The N-ter-
minus is followed by the collagen-like region which is
linked to the globular head by the neck. SP-A accumu-
lates in vivo predominantly as octadecamers composed
of six trimeric subunits forming a flower bouquet-like
structure [3,4]. The C-terminus with its globular domain
contains the recognition site for carbohydrates (CRD).
The intermolecular disulfide bonds at the N-terminal
end enable the aggregation of trimers to higher
oligomers.
In these formations SP-A participates in many physio-
logical functions, including the interaction of the CRD
with microorganisms, lectins or other molecules with
attached sugar sequences. The CRD is also a ligand for
phospholipids [5], involved in the regulation of the sur-
factant metabolism and phospholipid aggregation [6,7],
binds to macrophage membrane proteins [8] and to
type-II pneumocytes [9]. On the other hand SP-A can
interact with lipids through its collagen like domain. For
example, SP-A binds to dipalmitoylphosphatidylcholine
(DPPC), the major surfactant phospholipid [10,11].
Furthermore SP-A was found to have direct effects on
the survival of Gram-negative bacteria through mechan-
isms leading to increased permeability of the bacterial
cell membrane [12]. SP-A also affects a variety of
immune cell functions (reviewed in [13-15]) including
alveolar macrophages [16], neutrophils, lymphocytes and
dendritic cells [17].* Correspondence: matthias.griese@med.uni-muenchen.de
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In solution SP-A can self-agglutinate in presence of
calcium via its CRD [18]. The threshold concentration
of Ca2+ required was 0.5 mM for different species
[18,19]. However, the presence of trace amounts of Ca2+
was enough to induce SP-A self-agglutination in physio-
logical-ionic strength buffers at 37°C [20,21]. As shown
by Palaniyar et al., 1998 [22] SP-A self-associates further
into more ordered configuration of reversible, calcium-
dependent supraquaternary structures. The supraqua-
ternary structural form, in turn, forms extensive protein
networks when it interacts with phospholipid mono-
layers [22], possibly preventing collapse of the surfactant
lipid films in the presence of protein inhibitors, as they
occur in several disease conditions, including adult
respiratory distress syndrome or cystic fibrosis [23]. In
addition to these biophysical effects, the state of aggre-
gation of SP-A may be important for some of the other
effects, especially those on the functions of immune
cells [21]. Soluble SP-A had no effect on macrophage
production of reactive oxygen species but did stimulate
reactive oxygen production when SP-A was multiva-
lently presented after adherence to a surface [24,25].
Therefore the ability of SP-A to form SP-A self-associ-
ates, e.g. calcium-dependent supraquaternary SP-A
structures, may be a key variable of SP-A present in
physiological fluids. Thus a laboratory test is highly
desirable which assesses the capability of SP-A present
in a given sample to form aggregates. Such an assay was
developed by binding of SP-A via its N-terminus to
latex beads, so the presenting SP-A CRDs could interact
with each other and form visible agglutinates. Further
SP-A present in serum and BAL samples from patients
was analyzed. Here we describe the characteristics of the
test and the functional properties of SP-A in samples
from healthy controls, chronic bronchitis patients




Serum samples from four healthy individuals (mean age
20 years, 3 female) were used for the establishment of
the agglutination assay (see below), as described in the
legends to the figures in detail. For the investigation of
agglutination in patients with different diseases we used
samples from 10 patients with cystic fibrosis (2 patients
infected with Pseudomonas aeruginosa), 10 subjects with
chronic bronchitis and 7 additional healthy controls.
The clinical details of the subjects are depicted in Table
1. Written informed consent from the subjects was
obtained and the experimental research reported was
approved by our institutional ethics committee (EK65/
96).
BAL
BAL was performed as described [26] with 4 × 1 ml/kg
body weight normal saline warmed to body temperature.
The first aliquot of the recovered BAL fluid was treated
separately; all other samples were pooled for analysis.
The total cell count was measured in a hemocytometer;
the differential cell count was assessed from cytoprep
slides. Aliquots of the cell free BAL supernatant of the
pooled BAL sample were used for the analysis of total
protein.
Gel chromatography
To determine structural differences in BAL and serum
between the study populations a gel chromatography
method with a superose 6 column was chosen as
described [27]. In this method SP-A was separated with
regard to its oligomerization form. 1 ml BAL or 500 μl
serum were loaded. The larger the oligomers the earlier
they were eluted. After gel chromatography the SP-A
amount of the eluted fractions (800 μl) was determined
by Slot-Blot. The void volume of the column was about
6.8 ml eluting between fractions 8 and 9.
Slot blot
A slot blot was used to quantify SP-A concentration.
200 μl aliquots of the chromatography fractions and 100
μl standard recombinant human SP-A (gift of Dr. Wol-
fram Steinhilber, Nycomed, Konstanz, Germany) were
applied onto blot membranes in a Slot-Blot gadget
(BioRad, Munich, Germany). The membrane was
blocked with blocking buffer (2 g TWEEN, 6 g Fish
gelatine, 200 ml TBS: Tris-buffered saline, 50 mM Tris;
150 mM NaCl) for 3 h. After washing 3 times, the
membrane was incubated with a polyclonal recombinant
rabbit-anti-human SP-A antibody (Nycomed, Konstanz,
Germany) and 1% bovine serum albumin (BSA, Paesel
+Lorei, Duisburg, Germany) overnight. Following 3
washes for 10 min with TBS-T (TBS with 0.05%
Tween20) and incubation with the second goat-anti-rab-
bit antibody (1:10,000, Biozol, Eching, Germany) and 1%
BSA for 2 h, the membrane was washed finally. For sig-
nal detection the membrane was incubated for 1 min in
a mixture of 500 μl of each reagent from Super Signal
West Dura (Pierce, Bonn, Germany) and 1 ml of each
reagent from ECL Western Blot Detection Reagents (GE
Healthcare, Munich, Germany). Signals were measured
with a DIANA III camera (raytest, Straubenhardt, Ger-
many) by 15 min duration of exposure and evaluated by
AIDA Software (raytest, Straubenhardt, Germany). The
reproducibility of the slot-blot assay was good, as deter-
mined by the coefficient of variation at the highest con-
centration (41.6 ng/ml; rel CV 6.1%) of the standard
curve.
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SP-A self-agglutination measurement
An assay was designed to assess the ability of SP-A in
serum and broncho-alveolar lavage samples to aggluti-
nate. Schematically, anti-SP-A antibodies which bind
SP-A at its N-terminal end were coupled to 0.05 μm
beads, so that the bound SP-A was able to interact by
its C-terminal CRD with other SP-A molecules in a
given sample. This causes agglutination of the beads
forming larger aggregates, which were observed by light
microscopy (Figure 1).
To achieve this, 50 μl (1.82 × 1010 beads/ml) of a car-
boxylate-modified, streptavidin-labeled latex bead mix-
ture (Sigma Aldrich, Munich, Germany) was incubated
with 200 μl biotinylated rabbit anti-goat antibody (1.3
mg/ml, Dianova, Hamburg, Germany) for 18 h at 23°C
in 0.2 ml Eppendorf tubes (Eppendorf, Hamburg, Ger-
many). The mixture was washed 2 times with Hank
solution (8 g/l NaCl, 1 g/l glucose, 0.4 g/l KCl, 0.35 g/l
NaHCO3, 0.14 g/l CaCl2, 0.1 g/l MgCl2·6H2O, 0.06 g/l
Na2HPO4·2H2O, 0.06 g/l KH2PO4 and 0.06 g/l
MgSO4·7H2O, pH 7.4; Apotheke Innenstadt, University
Munich, Germany) and resuspended in 600 μl Hank
solution. Then 5 μl of the samples (final concentration
of SP-A derived from the peak fractions was 100 ng/ml
SP-A) were incubated with 2 μl bead suspension at 6.5
mM Ca2+, 3 μl pure water and 0.01 μg of the anti-SP-A
antibody (N19, Santa Cruz, Heidelberg, Germany) for 3
h at 4°C on a microscope slide (Menzel, Braunschweig,
Germany) under a cover slip (Menzel, Braunschweig,
Germany). To avoid non-specific agglutination of the
SP-A, all assays were done in the presence of 0.1% (v/v)
Triton X-100. Under the light-optical microscope
(Axioskop, Zeiss, Aalen, Germany) the biggest, pure
bead-agglutinate was searched and photographed. The
picture was viewed by the software Adobe Photoshop
(Adobe, Munich, Germany) at a size of 764×573 pixels.
Then, the size of the determined agglutinate was mea-
sured in pixel by drawing a square around it (Figure 1b).
For evaluating the reproducibility and sensitivity of the
assay 2 serum samples from healthy individuals (SP-A
concentration in serum was 20 ng/ml for both) were
tested by using serum volumes from 0 to 0.6 μl in 0.1 μl
steps (Figure 1c). The tests were repeated 3 times and
the coefficient of variation was between 1-5%.
Results
Characteristics of the assay to assess SP-A self-
agglutination
First the specificity for SP-A, and not for SP-D, and the
dependency of the assay on the presence of a complete
binding chain consisting of the beads coupled with the
anti-goat antibody, and the anti-human-SP-A antibody
was shown. Only the addition of SP-A (10 μl of a 100
ng/ml recombinant human SP-A) and the presence of
all components induced agglutination (Table 2). Recom-
binant human SP-D had no effect on agglutination
(Table 2).
Next the calcium and carbohydrate dependency of the
assay was assessed (Table 3). Results demonstrated that
an increasing concentration of mannose as well as the
absence of calcium inhibited the formation of large
agglutinates (Figure 2 and 3). On the other hand serum
and its many factors including SP-D, tested with serum
from patients with and without SP-D, had no effect on
SP-A self-agglutination (Tables 2 and 3). These data
confirmed the specificity of our assay for SP-A and not
SP-D and its utility for BAL and serum samples.
Analysis of serum samples
In 10 patients with cystic fibrosis the serum SP-A agglu-
tination ability was measured. The size of the aggluti-
nates was 1364 pixel ± 616 (range 667 to 2862) and did
not significantly differ from that obtained with the cor-
responding lavage fluid (1059 ± 346, range 560 to 1610).
Because the size of the SP-A agglutinates varied
between individuals and it is known that SP-A is present
in different oligomeric forms, we assumed that differ-
ences in the structural complexity may be responsible
for the variation observed. Therefore, we further ana-
lyzed the SP-A self-agglutination ability of the fractions
Table 1 Clinical data






Age 14 ± 3 (10) 4 ± 4 (10) 12 ± 8 (11)
Gender (% female) 6 (60) 8 (80) 3 (27)
BMI %, (n)
(overweight/normal/underweight)
40/30/30 (4/3/3) 0/100/0 (0/10/0) 0/100/0 (0/11/0)
Fev1 (% pred.) 97 ± 31 (10) 109 ± 15 (3) 118 (1)
SP-A level in serum (ng/ml) 26 ± 10 (10) 28 ± 24 (2) 17 ± 4 (10)
SP-A level in BAL (ng/ml) 4993 ± 2984 (10) 4094 ± 1363 (3) 6645 ± 5354 (11)
Neutrophils in BAL (%) 42 ± 29 (10) 9 ± 9 (5) 2.5 ± 4 (4)
Data are means ± SEM and range of (n) subjects.
Heinrich and Griese BMC Pulmonary Medicine 2010, 10:59
http://www.biomedcentral.com/1471-2466/10/59
Page 3 of 9
Figure 1 SP-A self-agglutination assay. a) The figure shows a scheme of the SP-A self-agglutination-assay. The streptavidin beads were
coupled to biotinylated rabbit anti-goat antibodies which bound goat anti-human SP-A antibodies. These anti-SP-A antibodies bound SP-A at its
N-terminal end, so SP-A could self-agglutinate by its CRD. The scheme attempts to illustrate the components of the reactants, but does not
render how the molecules bind exactly. b) The microscope pictures with a magnification of 10 times were taken under a light microscope.
Picture a shows an agglutinate while picture b illustrates beads without agglutination. c) The graph illustrates the SP-A dependency of the bead
agglutination. The agglutinate size is plotted against the amount of serum containing SP-A which was incubated with the beads, anti-goat
antibody and goat-anti-human antibody in a buffer with calcium ions. Two different sera were used (Black triangle, SP-A concentration 20 ng/ml,
sample 2 and balck square, SP-A concentration 21 ng/ml, sample 1) in the experiments which were repeated three times. The final SP-A amount
was in 0.6 μl serum about 16 pg.
Table 2 Components necessary to induce SP-A self-agglutination under the assay conditions used
Condition Reagent Agglutination
SP-A SP-D Goat-anti-human-SP-A antibody Anti-goat antibody
1 + - + + +
2 - + + + -
3 + - - + -
4 + - + - -
5 - - + + -
The table shows five different conditions of the bead-assay. The beads were incubated alternatively with anti-goat antibody, goat-anti-human antibody, SP-A
(1 ng recombinant human standard, final concentration 100 ng/ml) or SP-D (1 ng recombinant human standard, final concentration 100 ng/ml) in a buffer
containing calcium ions. The “+” means that the reagent was used. After incubation the mixture was analyzed by light microscopy and agglutination was only
detected under condition 1 when SP-A was added. The experiments were repeated three times.
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derived from gel chromatography, containing different
oligomeric structural forms of SP-A. Gel chromatogra-
phy usually yields three peaks containing the main dif-
ferent oligomeric structures: an initial peak represented
by fraction 10 (F10) containing the largest forms, i.e.
octadecamers (18 mers) or more complex structural
forms of SP-A, followed by the second peak represented
by fraction 15 (F15), containing 6 to 12 mers, and finally
the third peak represented by fraction 20 (F20) contain-
ing the smallest forms, i.e. di- and trimers or monomers.
Using the SP-A self-agglutination assay, each fraction
was analyzed adjusted with respect to the SP-A
concentration.
In sera of all three study populations, CF, bronchitis
and controls, there was a significant difference regarding
the SP-A self-agglutination ability between the fractions
(Figure 4a). There was a steady decrease in agglutinate
size from SP-A octadecamers or more complex struc-
tures, over the hexamers to the fraction of dimers and
trimers. Of interest, in serum the SP-A agglutinate sizes
of the fractions were equal comparing the sample
groups (Figure 4a).
Analysis of BAL samples
In contrast to serum, the SP-A derived from patient
BAL samples indicated a major impact on the ability of
the fractions to induce SP-A dependent agglutination.
For all BAL fractions the SP-A oligomers derived from
controls agglutinated significantly better than the SP-A
oligomers derived from patients. Also samples from the
bronchitis population agglutinated better than those
from CF patients (Figure 4b).
Comparing the SP-A self-agglutination ability of the
fractions between BAL and serum within the groups of
CF and bronchitis patients there was also a significant
difference (Figure 4a and 4b), but not in controls.
Regarding the two disease groups SP-A structures in
serum agglutinated significantly better than the corre-
sponding structures in BAL.
To test if qualitative changes within the SP-A from a
specific patient might be responsible for the observed
effects, certain gel-chromatography fractions of SP-A
present in different patients at different levels, were iso-
lated, the concentration adjusted and tested for their
capacity to agglutinate; no differences were found (data
not shown). This result suggests that the relative com-
position of the whole sample with respect to the differ-
ent oligomeric forms is responsible for its agglutination
activity and not potential differences among the oligo-
meric forms within a particular fraction.
In conclusion, these results showed that SP-A in
serum had a better functional ability than SP-A in BAL
from patients with CF or chronic bronchitis, but not
from controls. Also, in BAL of patients with a lung dis-
ease the self-agglutination ability of SP-A was dimin-
ished compared to controls. In all three study groups,
the more complex SP-A oligomers were, the better was
their self-agglutination ability.
Discussion
Systematic evaluation of the conditions to induce micro-
scopically visible aggregation of SP-A showed the depen-
dency of the test on the concentration of SP-A added
into the reaction, the presence of calcium, and dose-
Table 3 Tests for SP-A self-agglutination-assay dependency
Beads Goat-anti-human-SP-A antibody Anti-goat antibody Serum Ca2+ Agglutination
+ + + + - -
+ + + + + +
+ + + - + -
+ + + - - -
+ - + + + -
+ - - + + -
- + + + + -
+ + + SP-D - -
+ + + SP-D + -
+ + + - + with Mannose -
+ + + + + with Mannose -
+ + + +/without SP-D + +
+ + + +/+Triton X + -
The table shows twelve conditions of the bead assay with varying reagents: beads, anti-goat antibody, goat-anti-human antibody, human serum and calcium ions
(Ca2+). The “+” means that the reagent was used for incubation. Without SP-A and/or calcium ions in serum, and also with Mannose no agglutination was
detected. The experiments were repeated three times. For the last condition a concentration of 0.1% (v/v) Triton X-100 was used (0.3 μl Triton X-100 in 1 ml pure
water, 3 μl of this water were used for the assay). A final concentration of 100 ng/ml SP-A (1 ng) in test serum and 100 ng/ml SP-D standard (1 ng recombinant
human SP-D) were used.
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dependent inhibition by mannose. It was established
that SP-D alone, serum without SP-A or without SP-A
and SP-D did not induce aggregation. Further we
showed that the more complex the oligomeric structure
of SP-A present in a particular sample was, the better
was its capability to induce aggregation at a given total
concentration of SP-A. Comparing the SP-A agglutina-
tion ability of the fractions no differences were observed
for SP-A derived from serum independent of the pul-
monary disease state. In contrast, in BAL fluid, it was
Figure 2 Carbohydrate-dependency of the agglutination of beads by SP-A. a) The pictures were taken under a light microscope by a
10 time magnification. Anti-goat antibody coated beads were incubated with goat anti-human SP-A antibody, 5 μl serum and an increasing
amount of mannose (a: 0 mM mannose; b: 10 mM mannose; c: 20 mM mannose; d: 30 mM mannose; e: 40 mM mannose; f: 50 mM mannose).
The agglutinate size decreased corresponding to an increasing mannose concentration. b) The figure shows a graph of the agglutinate size out
of serum samples from three different test persons under varying mannose concentrations in a buffer containing calcium ions. SP-A
concentration was 21 ng/ml in sample 1, 20 ng/ml in sample 2, and 20 ng/ml in sample 3. The higher the mannose concentration was, the
smaller were the bead agglutinates. The experiments were repeated five times.
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clearly shown that patients with chronic bronchitis had
some, and those with cystic fibrosis had the most severe
impairments of SP-A capability to induce aggregation.
Thus, the agglutination assay was measuring the ability
of SP-A molecules to aggregate as an active process
induced in the assay. This ability was mainly a reflection
of the oligomeric structure of SP-A in the samples,
further of the origin of the samples and the disease
state.
The strength of this approach is the specific measure-
ment of the CRD binding of SP-A by a very simple and
fast method and the possibility for ex vivo analysis in
very small volume samples of serum and BAL. There is
also no step necessary to isolate the SP-A before the
measurement. As the goal of the study was to establish
the assay, the patient group sizes were relatively small.
However, the results were highly reproducible. Further
studies in larger populations are desirable and are
underway.
Our data confirm the calcium-dependency of SP-A
self-agglutination by its CRD, previously reported
[18,21,28]. Additionally, they are in agreement with pre-
vious authors supporting the thesis that the SP-A
self-agglutination capability may be important for its
function [24,25]. However, to what extent SP-A self-
agglutination capability correlates with anti-inflamma-
tory effects [29] or the many other modulatory effects in
different cell types, needs to be determined in studies
investigating several of these additional variables in
parallel.
We found that also smaller SP-A structures can agglu-
tinate, but as expected from in vitro data, to a lesser
extent than octadecamers. This data is important as for
Figure 3 Calcium-dependency of the bead-assay. The graph
displays the dependency on calcium ions of the bead agglutination
caused by SP-A. Serum samples of four test subjects (SP-A
concentrations see legends to figs. 1 and 2) were incubated with
beads, anti-goat antibody, goat-anti-human antibody in a buffer
containing calcium ions first without EDTA (black square) and then
with 50 mM EDTA (black triangle). Each experiment was repeated
five times. Removal of calcium by chelation with EDTA leads to
smaller bead agglutinates.
Figure 4 SP-A self-agglutination and fractions. The graphs show
the self-agglutination ability (y-axis) of different SP-A structures
derived from BAL (b) and serum (a) (x-axis) of the study populations.
The streptavidin beads were coupled to biotinylated rabbit anti-goat
antibodies which bound goat anti-human SP-A antibodies. These
anti-SP-A antibodies bound SP-A at its N-terminal end, so SP-A
could self-agglutinate by its CRD. The SP-A amount was adjusted to
1 ng (final concentration 100 ng/ml). All experiments were analyzed
by One way ANOVA. * stands for p < 0.05, ** for p < 0.01 and ***
for p < 0.001. In BAL and serum of all three study populations (10
CF, 10 Bro, 7 C) there was a significant difference between the self-
agglutination ability of the different structures (F10, F15 and F20).
The octadecamers or more complex structures showed the best
self-agglutination ability followed by the hexameric structures and
then the dimers/trimers. Comparing the self-agglutination ability
between the study groups, in all BAL fractions the SP-A oligomers
derived from controls agglutinated significantly better than the SP-A
oligomers derived from patients, while SP-A from bronchitis patients
agglutinated still better than from CF patients; except for F20 of
bronchitis samples, which showed the same self-agglutination
ability as controls. In contrast to BAL in serum there was no
difference between the study populations regarding the self-
agglutination ability of the different fractions (p > 0.05). Comparing
the agglutination ability between BAL and serum, only in the
patient populations (CF and Bro) all SP-A structures derived from
serum fractions agglutinated significantly better than the
corresponding structures derived from BAL. While in CF patients this
difference was highly significant for all structures in the bronchitis
study population the significance decreased from fraction 10 over
fraction 15 to fraction 20.
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the first time ex vivo SP-A from clinically well defined
patients with other lung diseases than pulmonary alveo-
lar proteinosis (PAP) was used extensively. SP-A from
PAP patients differs from normal SP-A, as the large
molecular structures are mostly non-reducible [30,31].
Furthermore, functional discrepancies were found to
non-proteinosis SP-A [32], as well as between recombi-
nant and native SP-A forms with respect to their self-
association ability [33].
SP-D is another lung collectin, also present in the
alveolar space and in serum, and shows structural simi-
larities to SP-A. SP-D monomers form trimers and four
trimers assemble to a cruciform structure with CRDs at
their end [34]. Similar to SP-A, SP-D can agglutinate
micro-organisms and bind to cells [35]. In previous stu-
dies we have also assessed its functional ability in sam-
ples from patients with various pulmonary diseases [36].
Of importance we demonstrated here no influence of
SP-D on our system.
The data clearly show a local pulmonary deficiency of
SP-A dependent agglutination in the pulmonary diseases
investigated, whereas no abnormalities were seen in sys-
temic circulation.
In future studies it will be important to investigate the
correlation of this assay with other functional properties
of SP-A, and more importantly the correlation with lung
function and long term disease outcome variables, in
order to determine its role as a surrogate marker and
potential modulator of the clinical course.
Conclusions
In summary, we describe the characteristics of the test
system to assess functional properties of SP-A in serum
and lavage samples. Samples from healthy controls,
bronchitis patients and patients with cystic fibrosis
induced SP-A self-association; the more complex the
SP-A structures were, the better were the self-agglutina-
tion abilities. Comparing the functional capabilities of
corresponding SP-A structures separated from serum
and BAL, in the two lung disease groups, BAL samples
had inferior SP-A self-agglutination abilities. This clearly
showed a strong structure - function relation of SP-A





Supported by a grant from the Mukoviszidose e.V and Vaincre la
Mucoviscidose to M. Griese.
Authors’ contributions
SMH carried out the microscopic and biochemical studies. MG conceived
the study. MG and SMH designed the experiments, performed the statistical
analysis and drafted the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 June 2010 Accepted: 22 November 2010
Published: 22 November 2010
References
1. Holmskov U, Thiel S, Jensenius JC: Collections and ficolins: humoral lectins
of the innate immune defense. Annu Rev Immunol 2003, 21:547-578.
2. McCormack FX: Structure, processing and properties of surfactant protein
A. Biochim Biophys Acta 1998, 1408:109-131.
3. King RJ, Simon D, Horowitz PM: Aspects of secondary and quaternary
structure of surfactant protein A from canine lung. Biochim Biophys Acta
1989, 1001:294-301.
4. Voss T, Eistetter H, Schafer KP, Engel J: Macromolecular organization of
natural and recombinant lung surfactant protein SP 28-36. Structural
homology with the complement factor C1q. J Mol Biol 1988, 201:219-227.
5. Palaniyar N, Ridsdale RA, Holterman CE, Inchley K, Possmayer F, Harauz G:
Structural changes of surfactant protein A induced by cations reorient
the protein on lipid bilayers. J Struct Biol 1998, 122:297-310.
6. Ikegami M, Jobe AH: Surfactant metabolism. Semin Perinatol 1993,
17:233-240.
7. McCormack FX, Damodarasamy M, Elhalwagi BM: Deletion mapping of N-
terminal domains of surfactant protein A. The N-terminal segment is
required for phospholipid aggregation and specific inhibition of
surfactant secretion. J Biol Chem 1999, 274:3173-3181.
8. Wintergerst E, Manz-Keinke H, Plattner H, Schlepper-Schafer J: The
interaction of a lung surfactant protein (SP-A) with macrophages is
mannose dependent. Eur J Cell Biol 1989, 50:291-298.
9. McCormack FX: Structure, processing and properties of surfactant protein
A. Biochim Biophys Acta 1998, 1408:109-131.
10. Haagsman HP, Sargeant T, Hauschka PV, Benson BJ, Hawgood S: Binding of
calcium to SP-A, a surfactant-associated protein. Biochemistry 1990,
29:8894-8900.
11. Kuroki Y, Akino T: Pulmonary surfactant protein A (SP-A) specifically binds
dipalmitoylphosphatidylcholine. J Biol Chem 1991, 266:3068-3073.
12. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS,
McCormack FX: Surfactant proteins A and D inhibit the growth of Gram-
negative bacteria by increasing membrane permeability. J Clin Invest
2003, 111:1589-1602.
13. Crouch EC: Collectins and pulmonary host defense. Am J Respir Cell Mol
Biol 1998, 19:177-201.
14. Eggleton P, Reid KB: Lung surfactant proteins involved in innate
immunity. Curr Opin Immunol 1999, 11:28-33.
15. Wright JR: Immunomodulatory functions of surfactant. Physiol Rev 1997,
77:931-962.
16. Tino MJ, Wright JR: Surfactant protein A stimulates phagocytosis of
specific pulmonary pathogens by alveolar macrophages. Am J Physiol
1996, 270:L677-L688.
17. Wright JR: Host defense functions of pulmonary surfactant. Biol Neonate
2004, 85:326-332.
18. Haagsman HP, Sargeant T, Hauschka PV, Benson BJ, Hawgood S: Binding of
calcium to SP-A, a surfactant-associated protein. Biochemistry 1990,
29:8894-8900.
19. Ruano ML, Miguel E, Perez-Gil J, Casals C: Comparison of lipid aggregation
and self-aggregation activities of pulmonary surfactant-associated
protein A. Biochem J 1996, 313(Pt 2):683-689.
20. Casals C, Ruano ML, Miguel E, Sanchez P, Perez-Gil J: Surfactant protein-C
enhances lipid aggregation activity of surfactant protein-A. Biochem Soc
Trans 1994, 22:370S.
21. Ruano ML, Garcia-Verdugo I, Miguel E, Perez-Gil J, Casals C: Self-
aggregation of surfactant protein A. Biochemistry 2000, 39:6529-6537.
22. Palaniyar N, Ridsdale RA, Possmayer F, Harauz G: Surfactant protein A (SP-
A) forms a novel supraquaternary structure in the form of fibers.
Biochem Biophys Res Commun 1998, 250:131-136.
23. Palaniyar N, Ikegami M, Korfhagen T, Whitsett J, McCormack FX: Domains
of surfactant protein A that affect protein oligomerization, lipid structure
Heinrich and Griese BMC Pulmonary Medicine 2010, 10:59
http://www.biomedcentral.com/1471-2466/10/59
Page 8 of 9
and surface tension. Comp Biochem Physiol A Mol Integr Physiol 2001,
129:109-127.
24. Gaynor CD, McCormack FX, Voelker DR, McGowan SE, Schlesinger LS:
Pulmonary surfactant protein A mediates enhanced phagocytosis of
Mycobacterium tuberculosis by a direct interaction with human
macrophages. J Immunol 1995, 155:5343-5351.
25. Weissbach S, Neuendank A, Pettersson M, Schaberg T, Pison U: Surfactant
protein A modulates release of reactive oxygen species from alveolar
macrophages. Am J Physiol 1994, 267:L660-L666.
26. Ratjen F, Rietschel E, Griese M, Ballmann M, Kleinau I, Doring G,
Reinhardt D, Paul K: Fractional analysis of bronchoalveolar lavage fluid
cytology in cystic fibrosis patients with normal lung function.
Bronchoalveolar lavage for the evaluation of anti-inflammatory
treatment (BEAT) study group. Eur Respir J 2000, 15:141-145.
27. Griese M, Maderlechner N, Ahrens P, Kitz R: Surfactant proteins A and D in
children with pulmonary disease due to gastroesophageal reflux. Am J
Respir Crit Care Med 2002, 165:1546-1550.
28. McCormack FX: Structure, processing and properties of surfactant protein
A. Biochim Biophys Acta 1998, 1408:109-131.
29. Sanchez-Barbero F, Strassner J, Garcia-Canero R, Steinhilber W, Casals C:
Role of the degree of oligomerization in the structure and function of
human surfactant protein A. J Biol Chem 2005, 280:7659-7670.
30. Hattori A, Kuroki Y, Katoh T, Takahashi H, Shen HQ, Suzuki Y, Akino T:
Surfactant protein A accumulating in the alveoli of patients with
pulmonary alveolar proteinosis: oligomeric structure and interaction
with lipids. Am J Respir Cell Mol Biol 1996, 14:608-619.
31. Voss T, Schafer KP, Nielsen PF, Schafer A, Maier C, Hannappel E, Maassen J,
Landis B, Klemm K, Przybylski M: Primary structure differences of human
surfactant-associated proteins isolated from normal and proteinosis
lung. Biochim Biophys Acta 1992, 1138:261-267.
32. Doyle IR, Davidson KG, Barr HA, Nicholas TE, Payne K, Pfitzner J: Quantity
and structure of surfactant proteins vary among patients with alveolar
proteinosis. Am J Respir Crit Care Med 1998, 157:658-664.
33. Sanchez-Barbero F, Rivas G, Steinhilber W, Casals C: Structural and
functional differences among human surfactant proteins SP-A1, SP-A2
and co-expressed SP-A1/SP-A2: role of supratrimeric oligomerization.
Biochem J 2007, 406:479-489.
34. Hansen S, Holmskov U: Structural aspects of collectins and receptors for
collectins. Immunobiology 1998, 199:165-189.
35. McCormack FX, Whitsett JA: The pulmonary collectins, SP-A and SP-D,
orchestrate innate immunity in the lung. J Clin Invest 2002, 109:707-712.
36. Hartl D, Griese M: Surfactant protein D in human lung diseases. Eur J Clin
Invest 2006, 36:423-435.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2466/10/59/prepub
doi:10.1186/1471-2466-10-59
Cite this article as: Heinrich and Griese: Assessment of Surfactant
Protein A (SP-A) dependent agglutination. BMC Pulmonary Medicine 2010
10:59.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Heinrich and Griese BMC Pulmonary Medicine 2010, 10:59
http://www.biomedcentral.com/1471-2466/10/59
Page 9 of 9
